Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.


NDAQ:MRNA - Post by User

Moderna Inc > WHO issues its first emergency use validation for a COVID-19
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(54)
•••
Comment by Richmondon Jan 05, 2021 3:42am
89 Views
Post# 32221943

RE:WHO issues its first emergency use validation for a COVID-19

RE:WHO issues its first emergency use validation for a COVID-19Who cares about WHO? WHO had conspired with China on Covid-19 ChinaVirus. Now is conspiring against MODERNA. Hells with what WHO thinks...
Active_Trader wrote: WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access to Pfizer/BioNTech $pfe $bntx 31 December 2020  News release Geneva ... $mrna Moderna is NOT approved by WHO.
https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access Carry on shorting Moderna for profits. All good here re Based on $104, since premarket past Monday +$65,633.94 , +31.35% roi over 4 days ... with more to follow. I ain't done wringing this Moderna bird's neck ... $MRNA ... sub $50 in queue. Follow me for profits, tdtiahth @Flash_Trader xo https://stocktwits.com/Flash_Trader


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities